Quantum BioPharma Launched Phase 2 MS Clinical Trial
The firm partnered with Thermo Fisher Scientific to test a new drug targeting myelin degradation in patients.
Updated on Oct. 6, 2026 in Quantum Computing
Live Poll
Do you trust that new pharmaceutical developments significantly improve outcomes for those with chronic illnesses?
Quantum BioPharma has initiated a Phase 2 clinical trial for Lucid-MS after securing FDA clearance. The company signed a study start-up agreement with Thermo Fisher Scientific to manage the project, which targets the PAD2 enzyme.
Why it matters
The trial aims to determine if Lucid-MS can effectively treat progressive multiple sclerosis by stopping or reversing myelin degradation. Researchers hope to assess patient tolerance and safety through clinical and radiological markers.
Lucid-MS is a chemical entity specifically designed to target the PAD2 enzyme. Initial preclinical studies suggested the drug could successfully prevent and reverse myelin degradation, with recent tests utilizing the [18F]3F4AP PET tracer for imaging.
The players
Quantum BioPharma
A pharmaceutical company focused on developing novel chemical entities for the treatment of neurological conditions.
Thermo Fisher Scientific
A global provider of scientific instrumentation, reagents, and clinical research services for the pharmaceutical industry.
The details
The randomized, double-blind, placebo-controlled study is being managed by the Thermo Fisher PPD clinical research business. Researchers are using clinical and radiological markers to monitor how the drug impacts myelin breakdown.
Timeline
Patient enrollment reached 50% in May 2026.
The partnership was announced on October 6, 2026.
The Tech Race
This development follows the established FDA drug development and clinical trial pathway to advance a new therapy for multiple sclerosis. The push to target specific enzymes like PAD2 represents a broader technological shift toward precision medicine in neurology.
This trial offers hope for future treatment options for those living with progressive multiple sclerosis. If successful, the drug could eventually provide a new standard of care for reversing neurological damage.
The takeaway
The move to Phase 2 marks a significant milestone in validating the potential for PAD2-targeted therapies. Patients and their families should continue to monitor clinical trial registry updates for future study results.
Further reading
Learn more about the latest innovations in Quantum Computing.
Live Poll
Do you trust that new pharmaceutical developments significantly improve outcomes for those with chronic illnesses?
